High Prevalence of Pneumothorax on PET‐CT Studies Performed in Lung Cancer Patients Following Post–Transthoracic Needle Biopsy Mandates Careful Scrutiny

Joseph Sommerfeldt, Timothy L. Miao, Lionel Sydney Zuckier, Ashish Gupta

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

ABSTRACT: In our practice, FDG PET-CT studies are frequently performed within days of transthoracic needle biopsy, often revealing presence of pneumothorax (PTX), a “critical finding” that should be reported expeditiously. In our experience, prevalence of PTX at PET-CT performed 1 day following biopsy is greater than 40%. Of these, approximately a third are not visible on the postprocedure chest radiography, as in a case we describe. A high level of vigilance is therefore recommended to identify PTX in patients who have undergone recent transthoracic needle biopsy, even when no PTX is present immediately following the biopsy procedure.

Original languageEnglish (US)
JournalClinical nuclear medicine
DOIs
StateAccepted/In press - Jun 5 2017
Externally publishedYes

Fingerprint

Needle Biopsy
Pneumothorax
Lung Neoplasms
Biopsy
Radiography
Thorax
Positron Emission Tomography Computed Tomography

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

@article{3f691bbadc2245d499f905ad5755f3d5,
title = "High Prevalence of Pneumothorax on PET‐CT Studies Performed in Lung Cancer Patients Following Post–Transthoracic Needle Biopsy Mandates Careful Scrutiny",
abstract = "ABSTRACT: In our practice, FDG PET-CT studies are frequently performed within days of transthoracic needle biopsy, often revealing presence of pneumothorax (PTX), a “critical finding” that should be reported expeditiously. In our experience, prevalence of PTX at PET-CT performed 1 day following biopsy is greater than 40{\%}. Of these, approximately a third are not visible on the postprocedure chest radiography, as in a case we describe. A high level of vigilance is therefore recommended to identify PTX in patients who have undergone recent transthoracic needle biopsy, even when no PTX is present immediately following the biopsy procedure.",
author = "Joseph Sommerfeldt and Miao, {Timothy L.} and Zuckier, {Lionel Sydney} and Ashish Gupta",
year = "2017",
month = "6",
day = "5",
doi = "10.1097/RLU.0000000000001716",
language = "English (US)",
journal = "Clinical Nuclear Medicine",
issn = "0363-9762",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - High Prevalence of Pneumothorax on PET‐CT Studies Performed in Lung Cancer Patients Following Post–Transthoracic Needle Biopsy Mandates Careful Scrutiny

AU - Sommerfeldt, Joseph

AU - Miao, Timothy L.

AU - Zuckier, Lionel Sydney

AU - Gupta, Ashish

PY - 2017/6/5

Y1 - 2017/6/5

N2 - ABSTRACT: In our practice, FDG PET-CT studies are frequently performed within days of transthoracic needle biopsy, often revealing presence of pneumothorax (PTX), a “critical finding” that should be reported expeditiously. In our experience, prevalence of PTX at PET-CT performed 1 day following biopsy is greater than 40%. Of these, approximately a third are not visible on the postprocedure chest radiography, as in a case we describe. A high level of vigilance is therefore recommended to identify PTX in patients who have undergone recent transthoracic needle biopsy, even when no PTX is present immediately following the biopsy procedure.

AB - ABSTRACT: In our practice, FDG PET-CT studies are frequently performed within days of transthoracic needle biopsy, often revealing presence of pneumothorax (PTX), a “critical finding” that should be reported expeditiously. In our experience, prevalence of PTX at PET-CT performed 1 day following biopsy is greater than 40%. Of these, approximately a third are not visible on the postprocedure chest radiography, as in a case we describe. A high level of vigilance is therefore recommended to identify PTX in patients who have undergone recent transthoracic needle biopsy, even when no PTX is present immediately following the biopsy procedure.

UR - http://www.scopus.com/inward/record.url?scp=85020247849&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020247849&partnerID=8YFLogxK

U2 - 10.1097/RLU.0000000000001716

DO - 10.1097/RLU.0000000000001716

M3 - Article

C2 - 28590297

AN - SCOPUS:85020247849

JO - Clinical Nuclear Medicine

JF - Clinical Nuclear Medicine

SN - 0363-9762

ER -